PEGMEMA Diblock Copolymer Micelles for High Drug Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing polymeric assemblies for drug delivery, particularly in cancer treatment, face challenges such as low drug loading capacity, incomplete drug conjugation leading to reactive sites, and non-capsulated drug aggregates, which result in undesired distribution and severe side effects.
Innovation Solution
Development of amphiphilic block copolymers forming well-defined micellar assemblies with high drug content and efficient conjugation, using cleavable linkers to release therapeutic agents under specific conditions, and potentially encapsulating additional drugs through non-covalent interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If polymeric assemblies are used for drug delivery, then drug accumulation in tumors is improved through EPR effect, but drug loading capacity is low
Solution Approach 1:
The patent employs micellar structures where hydrophobic drug molecules are nested within the hydrophobic core of amphiphilic block copolymer micelles. This nested arrangement allows high drug loading capacity while maintaining the overall micellar size suitable for EPR effect-mediated tumor accumulation.
Solution Approach 2:
The patent uses amphiphilic block copolymers composed of hydrophilic and hydrophobic blocks to form composite micellar structures. The hydrophobic blocks provide drug loading capacity through hydrophobic interactions, while the hydrophilic blocks ensure colloidal stability and enable EPR effect for tumor targeting.
2Ease of manufacture
If post-polymerization conjugation is used to attach drugs, then drug attachment is achieved, but incomplete conjugation leaves reactive sites causing harmful interactions
Solution Approach 1:
The patent incorporates drug-bearing monomers during the polymerization process itself, rather than attaching drugs after polymer formation. This preliminary action ensures complete conjugation of all reactive sites during chain growth, eliminating residual reactive groups that could cause harmful biological interactions.
Solution Approach 2:
The patent extracts the drug attachment step from the post-polymerization phase and integrates it into the polymerization process. By using drug-bearing monomers, the drug attachment occurs simultaneously with polymer chain formation, removing the problematic separate conjugation step that leaves reactive sites.
3Adaptability or versatility
If chemotherapy agents are distributed throughout the body, then broad coverage is achieved, but severe side effects occur in healthy tissues
Solution Approach 1:
The patent creates local quality differences through the micellar structure, where the hydrophobic core provides a localized environment for drug loading and the hydrophilic corona provides a biocompatible surface. This local differentiation enables the drug to be concentrated in the core while the outer surface interacts favorably with biological systems, reducing side effects.
Solution Approach 2:
The amphiphilic block copolymer micelle acts as an intermediary carrier between the hydrophobic chemotherapy agent and the aqueous biological environment. The micelle shields the toxic drug in its core while presenting a biocompatible hydrophilic surface, enabling targeted delivery to tumors via EPR effect and minimizing exposure to healthy tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution achieves high drug loading, reduces the amount of polymer administered, and minimizes side effects by targeted drug delivery, enhancing therapeutic efficacy while maintaining a well-defined structure.
Implementation Method 1
self-assembly of polymeric compounds is an attractive method for polymeric assembly formation
Implementation Method 2
Drug loading in such polymeric assemblies can be achieved by covalent attachment or physical encapsulation via hydrophobic interactions
Data Source
AI summary
This invention relates to polymer drug conjugates according to formula I, and their use for treatment of diseases such as cancer.